- #15 on 4/19 (just before)
** charts before earnings **
** charts after earnings **
Quest Diagnostics beats by $0.15, beats on revs; raises FY17 EPS guidance, reaffirms FY17 revs outlook:
- Reports Q1 (Mar) earnings of $1.33 per share, excluding non-recurring items, $0.15 better than the Capital IQ Consensus of $1.18; revenues rose 1.9% year/year to $1.9 bln vs the $1.87 bln Capital IQ Consensus.
- "Growth in the quarter was driven by expanding relationships with hospital health systems. Our agreement with PeaceHealth in the Pacific Northwest announced in the first quarter will further bolster growth later in the year."
- Co issues guidance for FY17, sees EPS of $5.45-5.60 (Prior $5.37-5.52), excluding non-recurring items, vs. $5.46 Capital IQ Consensus Estimate; sees FY17 revs of $7.64-7.72 bln vs. $7.67 bln Capital IQ Consensus Estimate. The company revised its diluted EPS estimates for full year 2017 results, reflecting higher than expected excess tax benefit related to stock-based compensation in the first quarter of 2017
No comments:
Post a Comment